Trial of BMS-986012 in Combination With Platinum and Etoposide
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/2/2017 |
| Start Date: | October 2016 |
| End Date: | August 2019 |
| Contact: | Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email: |
| Email: | Clinical.Trials@bms.com |
A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and
Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Male and Females 18 years of age or older
- Pulmonary SCLC documented by histology or cytology
- Extensive disease (Stage IV) SCLC
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Exclusion Criteria:
- Prior systemic therapy for lung cancer
- Symptomatic brain metastases
- Grade 2 peripheral neuropathy
- Active or chronic infection with human immunodeficiency virus (HIV), hepatitis B
virus (HBV), or hepatitis C virus (HCV
- Other active malignancies or prior malignancy within 2 years
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials